Check out Dr. Jane Popes Video on #RA and Interstitial Lung Disease from #ACR17. https://t.co/2QnNjBYFZf
— Dr. John Cush (@RheumNow) November 9, 2017
Check out my video from #ACR17 on Still's disease and Autoinflammatory Syndromes – from Bedside to Bench. https://t.co/HE9UDOL9ft
— Dr. John Cush (@RheumNow) November 9, 2017
Big Take Home Message from #ACR17 on influenza vaccination- AT Next MTX FUV- give the flu vaccine AND HOLD MTX for 2 weeks (Plenary Session) by Park et al. https://t.co/grfLQx0CYN pic.twitter.com/A3xOyZOu5m
— Dr. John Cush (@RheumNow) November 9, 2017
High #cardiovascular disease risk in autoimmune inflammatory #rheumatic conditions
Assess & treat CV risks
via @cgytz #ACR17#cardiac pic.twitter.com/MQ36FJRU1E— Dr Ai Lyn Tan (@DrAiLynTan) November 7, 2017
Big Take Home Message from #ACR17 on influenza vaccination- AT Next MTX FUV- give the flu vaccine AND HOLD MTX for 2 weeks (Plenary Session) by Park et al. https://t.co/grfLQx0CYN pic.twitter.com/A3xOyZOu5m
— Dr. John Cush (@RheumNow) November 9, 2017
Dr Jack Cush: Stills and Auto-Inflammatory Syndromes
#GAMECHANGER. Failure of RA guidelines. 67% of MTX mono fail. Combo DMARDs or scMTX is better #acr17 @rheumnow #443 pic.twitter.com/q4P0fk460V
— Janet (@Janetbirdope) November 8, 2017
#GAMECHANGER. More remission in early RA CATCH cohort over time despite less biologic use. ?why #acr17 @rheumnow #1814 pic.twitter.com/QpDAZ2LJ08
— Janet (@Janetbirdope) November 8, 2017
No difference in lung safety of Abatacept and TNFI and one study of more ILD with IFX vs ABA #137. #acr17 @rheumnow #526 pic.twitter.com/ugYBF7THKa
— Janet (@Janetbirdope) November 8, 2017
JHU experience with Rheumatic irAEs: inflammatory arthritis features differ by ICI regimen #2902 @cappelliMD @RheumNow #ACR17
— Cassandra Calabrese (@CCalabreseDO) November 8, 2017
#GAMECHANGER. Pts with early RA value pain control which is improving over recent years. #acr17 @rheumnow #2955 pic.twitter.com/PVPEqgavDY
— Janet (@Janetbirdope) November 8, 2017
Dr. Janet Pope: Therapy Effect on Radiographic Progression
Think you know septic arthritis? Revolutionary insights from Ziv Paz. Come to 6D at 11am. #ACR17 pic.twitter.com/4kGScGQkjZ
— Jonathan Hausmann MD (@hausmannMD) November 8, 2017
#ACR17 Rheumatology Roundup.Cush #11L biologics #2 CA; #1175 biologics infants; #141 Refractory RA; #1885 Epi of AOSD; #200 Gout Telemedicine ; #885 Voclosporin SLE GN. AKavanaugh #271 CD318; #1205 XRT OA? #661 Entheses; #1112 Pred Gout; #541 SIE; #2031 EMR labs; #144 MVA RA
— Dr. John Cush (@RheumNow) November 8, 2017
Cognitive processing abnormalities in fibromyalgia #ACR17 @RheumNow pic.twitter.com/xz3VuuVryS
— Philip Robinson (@philipcrobinson) November 8, 2017
Dr. Janet Pope: Interstitial Lung Disease and RA
Treatment strategies for sarcoidosis: Baughman Grutters lancet 2015 #ACR17 pic.twitter.com/K4C9jCxj10
— Suleman Bhana, MD (@DrBhana) November 7, 2017
Mtx is steroid sparing for acute sarcoidosis #ACR17 pic.twitter.com/guq4OPB7kV
— Christian Ammitzbøll (@cgytz) November 7, 2017
Who should have infliximab? #sarcoidosis #ACR17 pic.twitter.com/JtsKbJivfD
— Christian Ammitzbøll (@cgytz) November 7, 2017
The use of low dose aspirin as primary prevention of CV events in RA had similar risk of major NSAID toxicity and MACE as patients not on it. A larger cohort will be needed to confirm use of low dose aspirin for primary prevention of CV events in RA, Solomon #ACR17
— Dr. Antoni Chan (@synovialjoints) November 7, 2017
Excellent, methotrexate is not and strong trend towards being protective #ACR17 https://t.co/rYfcPLFzgh
— Richard Conway (@RichardPAConway) November 7, 2017
Autoinflammatory disorders and their underlying genetic mutations #5T115 #acr17 @RheumNow pic.twitter.com/daYa1O0BPo
— Olga Petryna (@DrPetryna) November 8, 2017
Does communication with your patients through an office electronic portal allow for better RA outcomes. acr2017 @rheumnow#2032
— William Shergy (@WShergy) November 8, 2017
@RheumNow Still’s doesn’t kill patients, immunosuppressants and MAS do #acr17 #AOSD #periodicfeversyndromes pic.twitter.com/uZlIEHmlu1
— Olga Petryna (@DrPetryna) November 8, 2017
Who does it best? Back to back comparison of #AOSD Diagnostic criteria @RheumNow #acr17 #5T115 pic.twitter.com/tRJLbAU0Qb
— Olga Petryna (@DrPetryna) November 8, 2017
#ACR17 2864. Unlike RF & ACPA status, anti acetylated Ab pos distinguishes good response to TNFi in RA, and retention pic.twitter.com/OxRw6Pfz7a
— Patrick Kiely (@pkiely500) November 8, 2017
Bench to bedside: Dr.Jack Cush @RheumNow & Dr.Daniel Kastner on genetics, manifestations&Rx of autoinflammatory syndromes #acr17 #5T155 pic.twitter.com/AdauZ3tDP3
— Olga Petryna (@DrPetryna) November 8, 2017
Dr. Paul Sufka: Pregnancy and Treatment
Dr. Jack Cush and Dr. Pete Salzmann (Eli Lilly and Company): Pain as a Differentiator
#2804 #acr17 nationwide stdy Taiwan: ⬆️risk of cerebrovasc event, plum edema, chromosom abnorm &fetal distress in #AS pregnancies @RheumNow pic.twitter.com/VcGfDVVmBu
— Olga Petryna (@DrPetryna) November 7, 2017
@LCalabreseDO talks Zika for the rheumatologist: short-lived arthralgia hands&feet, worse if pre-existing RA @RheumNow @HealioRheum #ACR17 pic.twitter.com/WySlfcjjze
— Cassandra Calabrese (@CCalabreseDO) November 7, 2017
Inflammatory arthritis treatment in immune related adverse events to checkpoint inhibitors #ACR17 @RheumNow pic.twitter.com/UuRG4MKYeY
— Philip Robinson (@philipcrobinson) November 7, 2017
How do you treat an RA pt who has completed ChemoRx and now has very active RA?
— Dr. John Cush (@RheumNow) November 7, 2017
#GAMECHANGER. Influence of gender in RA steroid users. Different comorbidities in women vs men. #acr17 @rheumnow #2388 pic.twitter.com/kIxffpJw2Y
— Janet (@Janetbirdope) November 7, 2017
#GAMECHANGER. GFR is abnormal in RA compared to population. ?true in all inflammatory diseases. #acr17 @rheumnow #2399 pic.twitter.com/j6vcKV0mrF
— Janet (@Janetbirdope) November 7, 2017
#GAMECHANGER. If not responding to tociluzimab in RA you can respond to switch to 200 mg sarilab #acr17 @rheumnow #2468 pic.twitter.com/SwinP50HT3
— Janet (@Janetbirdope) November 7, 2017
New Jak-1 selective inhibitor ABT-494 doesn’t look too bad #ACR17 @RheumNow pic.twitter.com/sAHVqJr31a
— Philip Robinson (@philipcrobinson) November 7, 2017
No increased risk of second malignancy in RA patients on biologics. #ACR17 @RheumNow #11L pic.twitter.com/YUfehZgzg8
— Dr. Paul Sufka (@psufka) November 7, 2017
Serious infections in RA more associated with disease activity than DMARDs/biologics. #ACR17 @RheumNow #2410 pic.twitter.com/rq050WvnPJ
— Dr. Paul Sufka (@psufka) November 7, 2017
Effect of live HZ vaccine in MTX-IR w/RA getting tofa or ADA +/- MTX: well-tolerated, higher HZ rates in tofa+MTX #2393 #ACR17 @RheumNow
— Cassandra Calabrese (@CCalabreseDO) November 7, 2017
Blunted coronary flow reserve in # Lupus & RA #ACR17 @RheumNow pic.twitter.com/dF3W8N3sYx
— Dr. shashank akerkar (@doctorakerkar) November 7, 2017
#2453 #acr17 no difference in disease activity&PRO with ADA after MTX d/c at 6mo:LDA 42%ADAvs40%ADA+MTX @RheumNow pic.twitter.com/EtxpmVAQyL
— Olga Petryna (@DrPetryna) November 7, 2017
Increased cytokines/chemokines associated w/ CVD risk factors among pre-symptomatic RA pts. #ACR17 @RheumNow #2154 https://t.co/dekbMUtDbH
— Dr. Rachel Tate (@uptoTate) November 7, 2017
How many new cases of Adult-onset Still's disease do you diagnose in the last year?
— Dr. John Cush (@RheumNow) November 7, 2017
No power doppler + low MUS gray scale scores in remission pts (DAS-28, CDAI, SDAI, RAPID-3) #ACR17@RheumNow #1879 https://t.co/uIHoDrKqfy pic.twitter.com/SSGCyzDDQ4
— Dr. Rachel Tate (@uptoTate) November 7, 2017